Table 1.
Demographic and clinical characteristics of patients enrolled in the study
| Variable | Placebo group (n = 177) | Quetiapine XR 150 mg group (n = 74) | Quetiapine XR 300 mg group (n = 179) | ||||
|---|---|---|---|---|---|---|---|
| Age (years), mean (SD) | 38.8 | (11.0) | 39.2 | (10.2) | 38.1 | (11.2) | |
| Sex, n (%) | Male | 76 | (42.9%) | 37 | (50.0%) | 86 | (48.0%) |
| Female | 101 | (57.1%) | 37 | (50.0%) | 93 | (52.0%) | |
| Diagnosis, n (%) | Bipolar I disorder | 51 | (28.8%) | 22 | (29.7%) | 51 | (28.5%) |
| Bipolar II disorder | 126 | (71.2%) | 52 | (70.3%) | 128 | (71.5%) | |
| No. of mood episodes, n (%) | ≥ 4 | 13 | (7.3%) | 4 | (5.4%) | 14 | (7.8%) |
| MADRS total score, mean (SD) | 30.8 | (6.4) | 30.2 | (6.8) | 30.9 | (6.9) | |
| HAM-D17 total score, mean (SD) | 23.1 | (2.8) | 23.3 | (3.4) | 23.0 | (3.0) | |
MADRS Montgomery-Åsberg Depression Rating Scale, HAM-D17 Hamilton Depression Scale 17-Item, SD standard deviation, XR extended release